The Biostatistics Core for the Baylor College of Medicine's Lymphoma SPORE will provide comprehensiveand centralized support that integrates the biostatistical activities of the research projects in this SPOREprogram.
The specific aims of this core are to: 1. coordinate and manage the statistical activities of the SPOREto ensure that investigators haveready access to biostatistical consultation; 2. provide biostatistical expertise in study planning and conduct of clinical trials and preclinicalvalidation experiments; 3. coordinate data management activities in close collaborationwith the Clinical Core; and 4. provide comprehensive support for data analysis including safety/toxicity monitoring, interimreviews of data, final analysis, and reporting.This Lymphoma SPORE application proposes iterative laboratory-clinical studies which entails scientific andstatistical input for the ensuing animal experiments and clinical trials. The Biostatistics Core personnel willincorporate sound experimental principles in study planning and development, implement a coordinated datamanagement system, and facilitate provision of timely and high-quality statistical analysis and datainterpretation. The Biostatistics Core of this SPORE application will draw support from existing members ofBaylor Cancer Center's Biostatistics Shared Resource who are highly experienced and have establishedcollaborations with the research members of this SPORE. Ultimately, the SPORE investigators in thisapplication will benefit from the infrastructure of the Biostatistics Core to ensure the implementation ofinnovative and high-quality translational studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA126752-01
Application #
7253733
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2007-04-01
Project End
2012-03-31
Budget Start
2007-09-11
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$120,663
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Brunetti, Lorenzo; Gundry, Michael C; Kitano, Ayumi et al. (2018) Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. J Vis Exp :
Xiong, Wei; Chen, Yuhui; Kang, Xi et al. (2018) Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther 26:963-975
Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Velasquez, Mireya Paulina; Bonifant, Challice L; Gottschalk, Stephen (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131:30-38
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Ngai, Ho; Tian, Gengwen; Courtney, Amy N et al. (2018) IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol 201:2141-2153
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139

Showing the most recent 10 out of 270 publications